When NIH 3T3 fibroblasts were transduced with a retroviral vector containing a cDNA for porcine pancreatic elastase 1 and cultured in the presence of affinity-purified human plasminogen, the exogenously added plasminogen was digested to generate the kringle 1-3 segment known as angiostatin, a potent angiogenesis inhibitor. This was evidenced by immunoblot analysis of the plasminogen digests using a monoclonal antibody specifically reacting with the kringle 1-3 segment, and by efficient inhibition of proliferation of human umbilical vein endothelial cells by the plasminogen digests isolated from the culture medium of 3T3 fibroblasts. However, when Lewis lung carcinoma cells were transduced with the same vector and injected subcutaneously into mice in their back or via the tail vein, their growth at the injection sites or in the lungs was markedly suppressed compared with the growth of similarly treated nontransduced Lewis lung carcinoma cells. Nevertheless, the transduced cells were able to grow as avidly as the control cells in vitro. Assuming that the elastase 1 secreted from the transduced cells is likely to be exempt from rapid inhibition by its physiological inhibitor, ␣ 1 -protease inhibitor, as shown in the inflammatory tissues, the elastase 1 secreted from the tumor cells may effectively digest the plasminogen that is abundantly present in the extravascular spaces and generate the kringle 1-3 segment in the vicinity of implanted tumor cell clusters. Although the selection of more profitable virus vectors and cells to be transduced awaits further studies, such a protease gene transfer strategy may provide us with a new approach to anti-angiogenesis gene therapy for malignant tumors and their metastasis in vivo. Cancer Gene Therapy (2000) 7, 589 -596
T he growth of malignant tumor cells has been shown to depend largely upon the formation of networks of feeding arteries; the formation of such networks is known as angiogenesis. 1, 2 By inhibiting the tumor-related angiogenesis, we should be able to restrict the tumor mass to within a certain limited size that would not manifest any clinical signs or symptoms; consequently, the tumor would remain in the so-called dormant state. 3 Thus, by controlling the tumor-related angiogenesis, we may establish an effective therapeutic measure after surgical intervention, chemotherapy, and radiation to prevent residual tumor cells from recurring and metastasizing, even though they may only be detectable microscopically. Indeed, a number of anti-angiogenic substances have been proposed thus far (e.g., angiostatin, either kringle 1-4 3 or kringle 1-3 4 of plasminogen, other kringle fragments derived from prothrombin 5 and hepatocyte growth factor, 6 thrombospondins-1 and 2, 7 and endostatin). 8 To this end, a variety of tumor angiogenesis-targeted gene therapies have been proposed; 9 -13 indeed, anti-angiogenesis gene therapy using an angiostatin cDNA appears to be promising.
Here we report a novel strategy in which protease gene cDNA is used to obtain satisfactory amounts of angiostatin from the plasminogen that is abundantly available in the extravascular spaces surrounding the tumor cells.
MATERIALS AND METHODS

Cells and culture media
NIH 3T3 (CRL-1658; American Type Culture Collection (ATCC), Manassas, Va), which is a mouse fibroblast cell line, Lewis lung carcinoma (LLC), which is a mouse lung carcinoma cell line (a kind gift of Shionogi & Co., Osaka, Japan), and Bosc 23, which is a transient ecotropic retrovirus packaging cell line (CRL-11554; ATCC) were maintained in Dulbecco's modified Eagle's medium (Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine sera (FBS) (Bioserum, Victoria, Australia), 100 U/mL penicillin, and 100 g/mL streptomycin (Irvine Scientific, Santa Ana, Calif) in a 5.0% CO 2 atmosphere at 37°C. Human umbilical vein endothelial cells (HUVECs) were isolated and grown essentially as described elsewhere.
14 Cells at the third to fourth passage were grown to confluence on fibronectin-coated plates with an EGM-2 bullet kit (BioWhittaker, Walkersville, Md). This medium kit contains 2.0% FBS, 50 mg/mL gentamycin, 50 g/mL amphotericin B, heparin, hydrocortisone, ascorbic acid, human basic fibroblast growth factor (bFGF), vascular endothelial cell growth factor, insulin-like growth factor, and human epidermal growth factor.
Plasmid construction
We constructed a polycistronic retrovirus vector plasmid containing a porcine pancreatic elastase 1 (ELS1) cDNA (Fig 1) 16, 17 Although LNCX has a neomycin resistance gene as a selectable marker under the control of the long terminal repeat promoter, CD8a-positive cells are selected using immunomagnetic beads as described previously. 18, 19 Briefly, the murine phosphoglycerate kinase promoter-neomycin phosphotransferase cassette (EcoRI-SalI) in the murine stem cell virus (MSCV) 2.2 retrovirus vector (a generous gift of Dr. R. G. Hawley, University of Toronto, Toronto, Canada) was replaced with the murine CD8a cDNA under the control of the EMCV-derived IRES (nucleotides 259 -833 of EMCV-R genome) to construct MSCV/IRES-CD8a. The XhoI-BamHI fragment containing the ELS1 cDNA was obtained from pCR 2.1/ELS1 20 (kindly provided by the Pharmaceutical Research Laboratory, Kirin Brewery Co., Takasaki, Japan) and ligated into the multicloning sites of MSCV/IRESCD8a (the XhoI site and the BamHI site, respectively) to obtain the ELS1 IRES-CD8a cassette. MSCV/ELS1 IRESCD8a was digested with BglII, blunted, and digested again with ClaI to obtain an ELS1 IRES-CD8a cassette as blunt-end ClaI fragments. These fragments were ligated with the HpaI-ClaI fragments of the backbone LNCX.
Retrovirus production, transduction, and selection Bosc 23 was transfected with LNC/ELS1 IRES-CD8a by the standard lipofection method using Lipofectamine (Life Technologies). The virus supernatant from the transfected Bosc 23 cells was harvested at 2 days posttransfection and used for transduction. After having been infected with retrovirus, the transduced cells were selected with a magnetic cell sorting system using an anti-murine CD8a antibody (Ab) conjugated to microbeads (Miltenyi Biotech, Auburn, Calif). The CD8a-positive cells were recovered according to the manufacturer's instructions and analyzed for CD8a expression with a FACScan (Becton Dickinson, San Jose, Calif) using fluorescein isothiocyanate-labeled anti-mouse CD8a Ab (PharMingen, San Diego, Calif). The selected cells were pooled and used in the following assays.
Expression of ELS1 cDNA
Expression of ELS1 of the transduced cells was confirmed by immunoblotting. Aliquots of 4 ϫ 10 6 cells were lysed with Nonidet P-40 lysis buffer (1% Nonidet P-40 in 150 mM tris(hydroxymethyl)aminomethane-HCl (pH 7.4) containing 1% aprotinin and 1 mM phenylmethylsulfonyl fluoride). The protein concentration of the lysates was determined using the bicinchoninic acid protein assay kit (Pierce, Rockford, Ill). The proteins were dissolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis 21 using 12% gels and electroblotted onto Immobilon-P polyvinylidene fluoride membranes (Millipore, Yonezawa, Japan). After blocking with 5% casein, the membranes were incubated with an anti-ELS1 rabbit Ab (Chemicon, Temecula, Calif); resolved proteins were visualized using the enhanced chemiluminescence system (Amersham, Little Chalfont, UK).
Protease activity of ELS1 in the culture media
The serum-free conditioned media from the transduced and nontransduced cells were harvested at 24 hours of culture. A total of 1 mL each of the conditioned media was treated with or without 50 ng/mL trypsin for 2 hours at 37°C. Next, 50 L of each sample was added to 200 L of 20 mM tris(hydroxymethyl)aminomethane-HCl (pH 8.0) containing 100 mM Nsuccinyl Ala-Pro-Ala 7-amino-4-methylcoumarin (Sigma, St. Louis, Mo) and incubated at 37°C. The reaction was terminated with 17% acetic acid at various time intervals, and absorbance at 460 nm after excitation at 380 nm was measured with a fluorescence spectrophotometer.
Assay for angiostatin produced in vitro
A total of 4 ϫ 10 6 transduced and nontransduced NIH 3T3 cells were cultured in medium containing 1% FBS (10-fold lower than the conventional concentration) for 24 hours. Affinity-purified human plasminogen 22 was added to the medium at 100 g/mL, and the cells were cultured for another 72 hours at 37°C. The culture media were applied to a lysineSepharose column (0.8 ϫ 2.0 cm), and the adsorbed proteins were eluted with 100 mM ⑀-amino caproic acid (⑀ ACA) and pooled. The pooled fractions were analyzed by SDS-polyacrylamide gel electrophoresis using 10% gels followed by immunoblotting and were tested for inhibition by adding 100 g/mL to the culture medium of HUVECs with or without 100 kallikrein inhibitor units per milliliter of aprotinin. After 72 hours of culture, viable cells were counted under a phase- contrast microscope. For statistical analysis, the Student's t test was used. A P value of Ͻ.05 was considered to be significant. 
Assay for implantation and growth of the transduced and nontransduced LLC cells in mice
Implantation to the lungs after intravenous (i.v.) injection.
A total of 1 ϫ 10 5 transduced and nontransduced LLC cells were individually injected into five and four mice, respectively, via the tail vein. The mice were sacrificed after 30 days, and the tumor cells implanted to the lungs were examined macroscopically. Growth of the implanted tumors was classified into five grades based on the extent of infiltration in the lung lobes. Grade 0: no visible tumor masses were present; grade 1: less than five small (Յ5 mm in diameter) nodular tumor masses were present; grade 2: five or more small nodular tumor masses were present; grade 3: a single large (Ͼ5 mm in diameter) tumor mass was present without any small nodular lesions; grade 4: one or more large tumor masses were present with small nodular lesions.
RESULTS
Selection of the retroviral vector-transduced cells NIH 3T3 fibroblast cells and LLC cells transduced with the polycistronic retrovirus vectors were successfully selected by magnetic cell sorting using an anti-murine CD8a Ab conjugated to microbeads. According to fluorescence-activated cell sorter analysis, Ͼ90% of the selected cells expressed CD8a on the cell surface ( Fig  2A) . All these cells were presumed to contain ELS1 cDNA, although the expression of ELS1 may not be extremely high because we used pooled cells but not the high-expression clones specifically selected. As for the growth of LLC cells, which will be used in an in vivo experiment, there was no significant difference between the transduced and nontransduced cells when cultured in the presence of 10% FBS (Fig 2B) .
Expression and functional analysis of ELS1 in transduced 3T3 and LLC cells Both transduced 3T3 and LLC cells were found to express ELS1, a 28-kDa protein, when the cell lysates were examined by immunoblotting (Fig 3, lanes 2 and 4 , respectively, as indicated by an arrowhead). Needless to say, no corresponding protein bands were noted in the cell lysates of nontransduced controls (Fig 3, lanes 1 and 3) .
We subsequently measured the elastase activity in the serum-free conditioned media collected at various time intervals, using a synthetic fluorescence substrate, Nsuccinyl-Ala-Pro-Ala methylcoumarin, which is specific for elastase. Because conversion of the proenzyme to an active enzyme is catalyzed by trypsin, we compared the elastase activities in the culture media with or without prior treatment with trypsin at an enzyme to substrate ratio of 1:100.
The elastase activity in the culture media of transduced cells was found to be very low at 2 hours of culture; however, this activity became distinct at 12 hours and further increased at 24 hours of culture irrespective of the prior treatment with trypsin (Fig 4, f, trypsin (Ϫ) and (ϩ)). Enzyme activity was also noted in the 12-hour and 24-hour samples of nontransduced cells, but the levels were distinctly low (Fig 4, Ⅺ) compared with those for the corresponding culture media of the transduced cells. Based on the immunoblot analysis data, this activity is most likely due to some endogenous elastase-like enzyme other than ELS1.
Modulation of plasminogen digestion by the ELS1 cDNA-transduced 3T3 cells
The ELS1 cDNA-transduced 3T3 cells were found to modulate time-dependent digestion of the plasminogen added to the culture medium. As noted in Figure 4 , a rather long incubation was needed to evidently show the elastase activity in the culture media, but such a longterm culture of transduced cells in the serum-free conditioned medium resulted in complete death of cells. In accordance with a widely accepted procedure, a variety of proteolytic enzymes were liberated from the dead transduced and nontransduced cells; consequently, plasminogen was degraded substantially. Based on these findings, we cultured the transduced and nontransduced cells in the medium containing 1.0% FBS instead of 10% for conventional cell cultures, and observed elastasecatalyzed plasminogen digestion modulated by the transduced cells. Immunoblot analyses of the culture media using an anti-human plasminogen rabbit Ab and two anti-kringle 1-3 monoclonal Abs (mAbs), JIPPI-3 23 and P 3 F 2, 24 clearly showed that plasminogen had been digested in a time-dependent manner in the culture media of transduced cells; at 48 hours and 72 hours of culture, the kringle 1-3 segment as a doublet had been generated (Fig 5 A and B, panel 2, indicated by arrowheads) . In the control sample from the nontransduced cell culture, only limited degradation was noted at 72 hours (Fig 5A, panel  1 ), but generation of the kringle 1-3 segment was undetectable even in the 72-hour sample (Fig 5B, panel 1) .
Effect on the cultured HUVECs of the plasminogen digests modulated by the transduced 3T3 cells To determine whether the plasminogen-derived digests modulated by the transduced 3T3 cells affect the proliferation of HUVECs in culture, we collected the plasminogen digests from the culture media of 3T3 cells by lysine-Sepharose affinity chromatography and added them to the culture media of HUVECs. At the fourth passage, 1 ϫ 10 5 HUVECs were cultured in the presence of the 72-hour digests of plasminogen (100 g/mL, isolated from the culture media together with 5 ng/mL bFGF) for 72 hours at 37°C, and viable cells were counted (for details, see Materials and Methods). Indeed, a highly significant reduction was noted in the number of viable HUVECs cultured with the transduced 3T3 cellmodulated plasminogen digests against two controls, namely, those cultured without plasminogen-derived fragments and those cultured with the nontransduced cell-modulated plasminogen-derived proteins (Fig 6,  lane 3 against lanes 1 and 2, respectively) .
Growth of LLC cells implanted s.c. into mice
When both transduced and nontransduced LLC cells were cultured in appropriate culture media, they were found to grow avidly and to become confluent in an identical fashion (profiles not shown). After 1 ϫ 10 6 transduced or nontransduced LLC cells had been implanted s.c. in the backs of mice, their volumes were sequentially measured and expressed in mm 3 . The nontransduced LLC cells were found to grow rapidly, reach- ing nearly 5000 mm 3 on day 12 and 7500 mm 3 on day 14 (Fig 7A, Ⅺ) , whereas the growth of the transduced LLC cells was obviously retarded, particularly in the initial stage, being measured at only 1000 mm 3 on day 12. Even on day 14, the transduced cell masses were found to be nearly one-half of the nontransduced cells (Fig 7A, f) . Consistent with the delayed growth of transduced LLC cells in vivo, the mice bearing the transduced cells were found to survive longer than those bearing the nontransduced cells (Fig 7B, solid line for mice bearing the transduced cells (n ϭ 7) and dotted line for those bearing the nontransduced cells (n ϭ 6)).
Implantation and growth of LLC cells in the lungs after i.v. injection
When the transduced and nontransduced LLC cells were injected to mice via the tail vein, they were implanted in the lungs and grew as solid tumors. To assess the growth of the implanted tumor cells, we tentatively classified the tumor growth into five grades according to the extent of tumor invasion. As summarized in Table 1 , the nontransduced cells were found to almost completely invade one or two lobes in three of four mice, and to invade two lobes with multiple (Ͼ7) nodules in one mouse. Although we defined the size of a large tumor mass to be Ͼ5 mm in diameter, all of the large tumors in these three mice were actually Ͼ10 mm in diameter; thus, the normal tissue appeared to be almost completely collapsed. On the contrary, a large tumor mass (7 mm in diameter) without any small nodular lesions was observed only in a single mouse injected with the transduced LLC cells. The other four mice developed only two or three small nodular lesions in one or two lobes (n ϭ 3), or no apparently visible tumor masses in any lobe (n ϭ 1). Photographs of representative lobes of the lung in these two groups of mice are shown (Fig 8, B and C, respectively) . Figure 8A indicates the normal control. A massive tumor of Ͼ10 mm in diameter is indicated by a large arrowhead (Fig  8B) , and small tumors are indicated by small arrowheads (Fig 8, B and C) . 
DISCUSSION
In this study, we have shown that cultured 3T3 fibroblasts transduced with a vector containing a cDNA coding for ELS1 were able to proteolytically degrade the plasminogen added to the culture medium and consequently generate the kringle 1-3 segment known as angiostatin 3, 4 ( Fig 5, A and B) . On the contrary, the vector nontransduced 3T3 cells failed to generate the kringle 1-3 segment under identical conditions, although the exogenously added plasminogen was degraded only to a limited extent, if at all, at 72 hours of culture.
When HUVECs were cultured in the presence of the plasminogen digests isolated from the culture medium of the transduced 3T3 cells, their growth was substantially inhibited irrespective of the presence of aprotinin. This inhibitory substance may well be the kringle 1-3 fragment, angiostatin, which was recently shown to be a potent regulator of angiogenesis.
Inhibition of cell growth was also shown in an in vivo experiment in which ELS1 cDNA-transduced LLC cells were injected s.c. into the backs of mice or via the tail vein and implanted into the lungs. In fact, the growth of the transduced LLC cells in the s.c. tissue of the back was distinctly delayed compared with that of the nontransduced cells. Consistent with the delayed growth of tumors, the survival time was prolonged. However, the mice injected i.v. with the nontransduced LLC cells were found to develop large tumor masses; these masses almost completely infiltrated one or two lung lobes in three of four mice. In one mouse, multiple (Ͼ7) nodular tumor masses were found in two lobes.
Attempts to conduct viral vector-targeted anti-angiogenic therapy have been reported recently using an angiostatin cDNA; the data appear to be attractive compared with the data obtained for bolus injections of anti-angiogenic factors. 9 -13 Long-term systemic delivery of anti-angiogenic proteins poses a number of difficult problems and, indeed, such a measure may not necessarily be logistically possible from a pharmacological standpoint for treating locally aggressive tumors or growth of residual tumor cells at the loci after surgical intervention or local irradiation. Although the fate of locally expressed and secreted angiostatin has not been amply elucidated, angiostatin per se is a degradation product of plasminogen, and thus would not be able to stay long at the loci. Angiostatin may exert its antiangiogenic function before being evacuated, but to accomplish this goal, sufficient quantities of angiostatin must be produced. At this stage of the investigation, however, this is still an enigma that remains to be solved in the future.
As an alternative therapeutic measure to overcome this problem, we have attempted to use a cDNA for proteases to generate the kringle 1-3 segment from the endogenous plasminogen that is abundantly available in the extravascular spaces. There are indeed a number of candidate proteases that are capable of digesting plasminogen to yield the kringle 1-3 segment (e.g., MME-3, -7, -9, and -12, [25] [26] [27] and combination of urokinase and a reductase). 28, 29 Here in this study, we have attempted to use a cDNA for a well-established protease (i.e., ELS1) that is able to generate the kringle 1-3 segment from plasminogen, and have obtained favorable results in transduced and nontransduced LLC cells were injected via the tail vein into five and four mice, respectively. The animals were sacrificed at 30 days postinjection, and the lungs were removed together with the heart. Both outer (upper panels) and inner (lower panels) surfaces of representative specimens from normal control mice (A), nontransduced LLC-bearing mice (B), and transduced LLC-bearing mice (C) are shown. Small and large tumor masses are indicated by corresponding arrowheads; the heart is indicted by an arrow combined with the letter H. both in vitro and in vivo experiments. Criticisms for this study may be raised against usage of the targeted tumor cells themselves transduced with the retrovirus vector containing a cDNA for ELS1. In this regard, our attempt appears to be impracticable in clinical situations. In fact, to obtain a long-term efficacy, some other vectors, such as adeno-associated virus vector, may be appropriate, because it has been shown that they are able to be directly injected into, for example, striated muscle cells. 30 Thereby, the injected virus vectors may be transduced into the muscle cells and will constitutively express proteases as a therapeutic gene. Unless the expressed proteases exert plasminogen digestion predominantly to generate the kringle 1-3 segment from plasminogen in the extravascular spaces surrounding the transduced muscle cells, several disadvantageous events can arise from this sort of therapy. For example, if the expressed proteases should get into the systemic blood circulation, they will digest several plasma proteins, including blood-clotting factors, or conversely, they may be rapidly neutralized by plasma protease inhibitors, including ␣ 1 -protease inhibitor, before generating the kringle 1-3 segment. To avoid these disadvantages, the expressed enzymes could be tethered to the surface of constitutive cells by modifying the enzyme with an additional transmembrane region. 31 Despite all these disadvantages, an attempt to insert a cDNA for ELS1 into a virus vector seems to be a unique approach, and may be expanded to other protease cDNAs and viral vectors for clinical applications in the future.
